Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason P. Rhodes Sells 782 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now owns 15,962 shares of the company’s stock, valued at $528,342.20. This represents a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dyne Therapeutics Stock Performance

DYN traded up $0.95 during midday trading on Monday, reaching $29.34. The company had a trading volume of 1,268,326 shares, compared to its average volume of 1,493,931. The business has a 50-day moving average price of $32.48 and a two-hundred day moving average price of $35.24. Dyne Therapeutics, Inc. has a 12-month low of $10.03 and a 12-month high of $47.45. The stock has a market cap of $2.99 billion, a PE ratio of -7.97 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 earnings per share for the current year.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the period. Quantbot Technologies LP purchased a new position in Dyne Therapeutics in the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd purchased a new position in Dyne Therapeutics in the 3rd quarter worth approximately $36,000. US Bancorp DE boosted its stake in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at $62,000. Institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Chardan Capital reiterated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Stifel Nicolaus lifted their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. Morgan Stanley boosted their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.